The overexpression of HER2 has led to the development of targeted therapies, most notably trastuzumab (Herceptin). Trastuzumab is a monoclonal antibody that binds to the HER2 receptor, inhibiting its activity and promoting immune-mediated destruction of the cancer cells. Other HER2-targeted therapies include pertuzumab, lapatinib, and T-DM1. These treatments have significantly improved the prognosis for patients with HER2-positive cancers.
